Moderna Inc (NASDAQ:MRNA) has earned a consensus recommendation of “Buy” from the ten research firms that are presently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have covered the stock in the last year is $26.30.
Several research analysts have commented on MRNA shares. Needham & Company LLC reissued a “buy” rating and set a $28.00 price target on shares of Moderna in a research note on Monday, August 12th. Zacks Investment Research raised shares of Moderna from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Saturday, August 10th. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 target price on shares of Moderna in a research note on Sunday, June 2nd. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $24.00 target price on shares of Moderna in a research note on Sunday, August 11th. Finally, Morgan Stanley set a $30.00 target price on shares of Moderna and gave the stock a “buy” rating in a research note on Friday, August 9th.
Shares of MRNA stock traded up $0.31 during trading hours on Friday, hitting $16.71. 3,162,200 shares of the company’s stock were exchanged, compared to its average volume of 1,293,144. The stock has a market capitalization of $5.64 billion and a P/E ratio of -3.38. Moderna has a 12-month low of $11.54 and a 12-month high of $29.79. The stock has a 50 day simple moving average of $14.16.
Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.01. The business had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $18.80 million. As a group, sell-side analysts anticipate that Moderna will post -1.62 EPS for the current fiscal year.
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Featured Article: What is a dividend reinvestment plan?
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.